Loading
SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.
SSGJ-705 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and HER2. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-HER2 bispecifc antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials. The largest, NCT07022002, plans to enrol 340 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.SSGJ-705 binds PD-1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SSGJ-705" OR ABSTRACT:"SSGJ-705") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSGJ-705, not a curated reading list.
Shares SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors, 3SBio, HER2 and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares HER2 and the tag pipeline.